Patent ID: 11970715
Assignee: GENEMEDICINE CO., LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 3:
4. A method for treating a solid tumor in a subject in need thereof, comprising a step of administering a pharmaceutical composition comprising (a) a therapeutically effective amount of a polymer-virus complex and (b) a pharmaceutically acceptable carrier to the subject,
wherein a polymer of the polymer-virus complex of (a) is a pH-sensitive and bioreducible polymer, and a virus of the polymer-virus complex of (a) is an oncolytic virus having cancer-specificity, wherein the pH-sensitive and bioreducible polymer is bounded to a surface of the virus; and
wherein the pH-sensitive and bioreducible polymer comprises (i) an escapable portion from immune reactions, (ii) a chargeable portion having one or more amine groups and (iii) a bioreducible portion including one or more disulfide linkages,
wherein the escapable portion of (i) is bound to the chargeable portion of (ii), and is selected from the group consisting of PEG (polyethylene glycol), mPEG (methoxy polyethylene glycol), and a combination thereof;
wherein the chargeable portion of (ii) is piperazine or 1-(2-aminoethyl)piperazine;
wherein the bioreducible portion of (iii) is bound to the chargeable portion of (ii), and is N,N-cystaminebisacrylamide; and
wherein said pH-sensitive and bioreducible polymer comprises PEI-Arg (polyethyleneimine-arginine) additionally bonded at the end of the bioreducible portion;
wherein the solid tumor is selected from the group consisting of breast cancer, pancreatic tumor, lung cancer, uterine cancer, colon cancer, skin cancer, gastric cancer, bone cancer (osteosarcoma), brain stem glioma, bladder cancer, kidney renal cancer, liver cancer, ovarian cancer, cervical cancer, and prostate cancer.